Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies

Investigational New Drugs

Volumn 33, Issue 3, 2015, Pages 652-663

  Smith, David C ^a   Kalebic, Thea ^b   Infante, Jeffrey R ^c   Siu, Lillian L ^d   Sullivan, Daniel ^e   Vlahovic, Gordana ^f   Kauh, John S ^g   Gao, Feng ^b   Berger, Allison J ^b   Tirrell, Stephen ^b   Gupta, Neeraj ^b   Di Bacco, Alessandra ^b   Berg, Deborah ^b   Liu, Guohui ^b   Lin, Jianchang ^b   Hui, Ai Min ^b   Thompson, John A ^h  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f DUKE CANCER INSTITUTE   (United States)

^g EMORY UNIVERSITY   (United States)

^h SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

20S proteasome; Activating transcription factor 3; Ixazomib; Non hematologic malignancies; Phase 1 clinical trial (4 6)

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; BORON DERIVATIVE; GLYCINE; IXAZOMIB; PROTEASOME INHIBITOR;

ADULT; AGED; ANALOGS AND DERIVATIVES; CANCER STAGING; CLINICAL TRIAL; COHORT ANALYSIS; DOSE RESPONSE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS; PATHOLOGY; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME;

ACTIVATING TRANSCRIPTION FACTOR 3; ADULT; AGED; BORON COMPOUNDS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLYCINE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PROTEASOME INHIBITORS; TREATMENT OUTCOME;

EID: 84939984782     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-015-0230-x     Document Type: Article

References (38)

1. Ciechanover A, Schwartz AL (1998) The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc Natl Acad Sci U S A 95(6):2727-2730
2. Hershko A (2005) Early work on the ubiquitin proteasome system, an interview with Avram Hershko. Interview by CDD. Cell Death Differ 12(9):1158-1161
3. McBride A, Ryan PY (2013) Proteasome inhibitors in the treatment of multiple myeloma. Expert Rev Anticancer Ther 13(3):339-358
4. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JL (2012) Proteasome inhibitors in multiple myeloma: 10 years later. Blood 120(5):947-959
5. Orlowski RZ, Kuhn DJ (2008) Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14(6):1649-1657
6. Reinstein E, Ciechanover A (2006) Narrative review: protein degradation and human diseases: the ubiquitin connection. Ann Intern Med 145(9):676-684
7. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C, Daud A, Spriggs DR (2002) A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8(8):2505-2511
8. Blaney SM, Bernstein M, Neville K, Ginsberg J, Kitchen B, Horton T, Berg SL, Krailo M, Adamson PC (2004) Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol 22(23):4804-4809
9. Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ, Stadler WM (2004) Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol 22(1):115-119
10. Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero R, Chachoua A, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Yee H, Zeleniuch-Jacquotte A, Wright J, Elliott P, Adams J, Muggia FM (2005) Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol 23(25):6107-6116
11. Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S, Russo P, Mazumdar M, Motzer RJ (2004) Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 22(18):3720-3725
12. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22(11):2108-2121
13. Shah MH, Young D, Kindler HL, Webb I, Kleiber B, Wright J, Grever M (2004) Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 10(18 Pt 1):6111-6118
14. Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, Fanourakis G, Tseleni-Balafouta S, Ain KB, Mitsiades N (2006) Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab 91(10):4013-4021
15. Yin D, Zhou H, Kumagai T, Liu G, Ong JM, Black KL, Koeffler HP (2005) Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 24(3):344-354
16. Cusack JC (2003) Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 29(Suppl):121-131
17. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59(11):2615-2622
18. Schenkein DP (2005) Preclinical data with bortezomib in lung cancer. Clin Lung Cancer 7(2):S49-S55
19. Dick LR, Fleming PE (2010) Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 15(5-6):243-249
20. Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, Yu J, Yang Y, Hales P, Bruzzese F, Liu J, Blank J, Garcia K, Tsu C, Dick L, Fleming P, Yu L, Manfredi M, Rolfe M, Bolen J (2010) Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 70(5):1970-1980
21. Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, Richardson P, Anderson KC (2011) In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 17(16):5311-5321
22. Lee EC, Fitzgerald M, Bannerman B, Donelan J, Bano K, Terkelsen J, Bradley DP, Subakan O, Silva MD, Liu R, Pickard M, Li Z, Tayber O, Li P, Hales P, Carsillo M, Neppalli VT, Berger AJ, Kupperman E, Manfredi M, Bolen JB, Van NB, Janz S (2011) Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res 17(23):7313-7323
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van GM, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
24. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26(7):1148-1159
25. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ (2000) Proteasome inhibition measurements: clinical application. Clin Chem 46(5):673-683
26. Assouline S, Chang JE, Cheson BD, Rifkin R, Hamburg S, Reyes R, Hui A-M, Gupta N, Di Bacco A, Shou Y, Martin P (2012) Results of a phase 1 dose-escalation study of once-weekly MLN9708, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma (Abstract). Blood 120:3646
27. Kumar SK, Bensinger WI, Zimmerman TM, Reeder CB, Berenson JR, Berg D, Hui AM, Gupta N, Di BA, Yu J, Shou Y, Niesvizky R (2014) Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood 124(7):1047-1055
28. Merlini G, Sanchorawala V, Zonder JA, Kukreti V, Schonland SO, Jaccard A, Dispenzieri A, Cohen AD, Berg D, Liu G, Di Bacco A, Gupta N, Hui A-M, Palladini G, Comenzo RL (2012) MLN9708, a novel, investigational oral proteasome inhibitor, in patients with relapsed or refractory light-chain amyloidosis (AL): results of a phase 1 study (Abstract). Blood 120:731
29. Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, Talpaz M, Berg D, Liu G, Yu J, Gupta N, Di BA, Hui AM, Lonial S (2014) Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood 124(7):1038-1046
30. Jiang HY, Wek SA, McGrath BC, Lu D, Hai T, Harding HP, Wang X, Ron D, Cavener DR, Wek RC (2004) Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response. Mol Cell Biol 24(3):1365-1377
31. Pan Y, Chen H, Siu F, Kilberg MS (2003) Amino acid deprivation and endoplasmic reticulum stress induce expression of multiple activating transcription factor-3 mRNA species that, when overexpressed in HepG2 cells, modulate transcription by the human asparagine synthetase promoter. J Biol Chem 278(40):38402-38412
32. Zimmermann J, Erdmann D, Lalande I, Grossenbacher R, Noorani M, Furst P (2000) Proteasome inhibitor induced gene expression profiles reveal overexpression of transcriptional regulators ATF3, GADD153 and MAD1. Oncogene 19(25):2913-2920
33. Zhou Q, Gallo JM (2011) The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacologyto the clinic. AAPS J 13(1):111-120
34. Keizer RJ, Schellens JHM, Beijnen JH, Huitema ADR (2011) Pharmacodynamic biomarkers in model-based drug development in oncology. Curr Clin Pharmacol 6(1):30-40
35. Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo M, Merlini G, Voorhees P, Chng WJ, Mazumder A, Usmani S, Einsele H, Comenzo R, Orlowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, Dimopoulos M, Lonial S, Jagannath S, Blade J, Miguel JS, Morgan G, Anderson KC, Durie BG, Sonneveld P (2012) Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 26(4):595-608
36. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S (2012) A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120(14):2817-2825
37. Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS (2012) An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 119(24):5661-5670
38. Papadopoulos KP, Burris HA III, Gordon M, Lee P, Sausville EA, Rosen PJ, Patnaik A, Cutler RE Jr, Wang Z, Lee S, Jones SF, Infante JR (2013) A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol 72(4):861-868